Total Payments
$937,192
2024 Payments
$199,468
Companies
31
Transactions
692
Medicare Patients
214
Medicare Billing
$16,385
Payment Breakdown by Category
Consulting$602,853 (64.3%)
Research$162,395 (17.3%)
Other$87,699 (9.4%)
Travel$75,174 (8.0%)
Food & Beverage$8,991 (1.0%)
Education$79.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $602,853 | 150 | 64.3% |
| Unspecified | $162,395 | 252 | 17.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,414 | 19 | 9.0% |
| Travel and Lodging | $75,174 | 115 | 8.0% |
| Food and Beverage | $8,991 | 153 | 1.0% |
| Honoraria | $3,285 | 2 | 0.4% |
| Education | $79.99 | 1 | 0.0% |
Payments by Type
General
$774,797
440 transactions
Research
$162,395
252 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $277,283 | 127 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $169,622 | 230 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $95,127 | 33 | $0 (2024) |
| LEO Pharma AS | $87,008 | 36 | $0 (2022) |
| AbbVie Inc. | $51,098 | 68 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $33,936 | 36 | $0 (2024) |
| PFIZER INC. | $24,483 | 22 | $0 (2024) |
| UCB, Inc. | $23,280 | 9 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $23,124 | 19 | $0 (2024) |
| UCB SA | $17,976 | 11 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $199,468 | 125 | SANOFI-AVENTIS U.S. LLC ($59,838) |
| 2023 | $173,505 | 123 | GENZYME CORPORATION ($80,334) |
| 2022 | $153,921 | 88 | GENZYME CORPORATION ($95,449) |
| 2021 | $98,660 | 74 | Regeneron Pharmaceuticals, Inc. ($31,591) |
| 2020 | $84,551 | 52 | LEO Pharma AS ($32,496) |
| 2019 | $123,253 | 87 | LEO Pharma AS ($33,765) |
| 2018 | $50,801 | 83 | AbbVie, Inc. ($13,874) |
| 2017 | $53,033 | 60 | Regeneron Pharmaceuticals, Inc. ($22,545) |
All Payment Transactions
692 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,387.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $11,460.00 | General |
| Category: Immunology | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $637.70 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $525.08 | Research |
| Study: A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $255.10 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $252.60 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Consulting Fee | Cash or cash equivalent | $8,580.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $428.95 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $282.56 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $220.54 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $134.71 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $73.62 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $46.86 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $41.76 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | Cash or cash equivalent | $39.50 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $34.56 | General |
| Category: DERMATOLOGY | ||||||
| 11/04/2024 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 10/26/2024 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,011.00 | General |
| Category: Immunology | ||||||
| 10/25/2024 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: CIBINQO CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 10/24/2024 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: CIBINQO CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 10/22/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $991.50 | General |
| 10/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $3,913.57 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $1,135.00 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $640.68 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $516.60 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $59,154 | 88 |
| AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | Regeneron Pharmaceuticals, Inc. | $25,465 | 44 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $13,410 | 14 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $7,973 | 17 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $6,832 | 11 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $6,408 | 14 |
| An Open-Label, Drug-Drug Interaction Study to Examine the Effects of Dupilumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Patients With Moderate to Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $5,544 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $5,023 | 6 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $4,888 | 5 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $4,306 | 4 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | Regeneron Pharmaceuticals, Inc. | $3,983 | 4 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $2,750 | 7 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | GENZYME CORPORATION | $2,250 | 6 |
| A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $2,000 | 5 |
| CIBINQO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| M16-048 | AbbVie, Inc. | $1,776 | 2 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $1,573 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients greater than or equal to 12 to less than 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | GENZYME CORPORATION | $1,250 | 1 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | Regeneron Pharmaceuticals, Inc. | $1,077 | 1 |
| A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months to < 6 Years With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $1,000 | 3 |
| Atopic Journey Using Real World data | GENZYME CORPORATION | $750.00 | 2 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | SANOFI-AVENTIS U.S. LLC | $717.04 | 2 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $538.48 | 2 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, >=6 Years to <12 Years of Age, With Severe Atopic Dermatitis | GENZYME CORPORATION | $500.00 | 1 |
| SOLO 1; SOLO 2; ADP2b | SANOFI-AVENTIS U.S. LLC | $472.43 | 1 |
| SOLO 1; SOLO 2 | SANOFI-AVENTIS U.S. LLC | $287.32 | 1 |
| OLE | SANOFI-AVENTIS U.S. LLC | $177.85 | 1 |
| MAINTAIN OLE | SANOFI-AVENTIS U.S. LLC | $130.56 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 53 | 71 | $12,124 | $4,564 |
| 2022 | 2 | 42 | 52 | $8,723 | $3,293 |
| 2021 | 2 | 64 | 86 | $14,797 | $5,553 |
| 2020 | 2 | 55 | 69 | $10,449 | $2,975 |
Total Patients
214
Total Services
278
Medicare Billing
$16,385
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 39 | 57 | $10,374 | $3,851 | 37.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 14 | $1,750 | $713.25 | 40.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 39 | $7,098 | $2,700 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 13 | $1,625 | $593.06 | 36.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 51 | 71 | $12,922 | $4,861 | 37.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 15 | $1,875 | $692.25 | 36.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 25 | 32 | $5,824 | $1,711 | 29.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 30 | 37 | $4,625 | $1,265 | 27.3% |
About Dr. Lisa Beck, M.D
Dr. Lisa Beck, M.D is a Dermatology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780649681.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lisa Beck, M.D has received a total of $937,192 in payments from pharmaceutical and medical device companies, with $199,468 received in 2024. These payments were reported across 692 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($602,853).
As a Medicare-enrolled provider, Beck has provided services to 214 Medicare beneficiaries, totaling 278 services with total Medicare billing of $16,385. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Rochester, NY
- Active Since 04/20/2006
- Last Updated 07/05/2023
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1780649681
Products in Payments
- DUPIXENT (Biological) $392,431
- DUPIXENT DUPILUMAB INJECTION (Biological) $48,079
- DUPIXENT (Drug) $31,105
- CIBINQO (Drug) $18,658
- TAPINAROF (Drug) $17,683
- FASENRA (Drug) $11,633
- NO PRODUCT DISCUSSED (Drug) $7,715
- Humira (Biological) $5,097
- XOLAIR (Biological) $4,306
- EUCRISA (Drug) $3,285
- FASENRA (Biological) $1,800
- Zoryve (Drug) $1,500
- RINVOQ (Drug) $650.00
- Xolair (Biological) $249.46
- AYVAKIT (Drug) $103.80
- ILARIS (Biological) $100.78
- DERMATITIS - DISEASE (Drug) $100.00
- RINVOQ (Biological) $60.54
- TALTZ (Drug) $22.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Rochester
Brett Shulman, Md, MD
Dermatology — Payments: $48,527
Dermatology $48,527
Afsaneh Alavi, Md, MD
Dermatology — Payments: $46,196
Dermatology $46,196
Anna De Benedetto, M.d, M.D
Dermatology — Payments: $41,746
Dermatology $41,746
Elizabeth Arthur, M.d, M.D
Dermatology — Payments: $20,989
Dermatology $20,989
Dr. John Tu, Md, MD
Dermatology — Payments: $15,516
Dermatology $15,516
Dr. Manasi Ladrigan, Md, MD
Dermatology — Payments: $15,181
Dermatology $15,181